Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though investors are watching for more detail.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.